Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BA1104 + BA1106
- Development stage
- Unknown
- Lead developer
- Boan Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BA1104 + BA1106 is an investigational combination cancer immunotherapy developed by Boan Biotech (a subsidiary of Luye Pharma). The combination consists of BA1104, a proposed biosimilar of the PD-1 inhibitor nivolumab (Opdivo), and BA1106, a proprietary, non-IL-2-blocking anti-CD25 monoclonal antibody. BA1106 selectively targets CD25-overexpressing regulatory T cells (Tregs) to deplete them via antibody-dependent cellular cytotoxicity (ADCC) while preserving IL-2 signaling and sparing effector T cells (Teffs). By combining Treg depletion with PD-1 checkpoint inhibition, the regimen aims to synergistically enhance anti-tumor immune responses. The combination is being evaluated in clinical trials for advanced solid tumors, including non-small cell lung cancer (NSCLC) and gastric cancer.
- Other names
- BA1104 + BA1106BA1104 in combination with BA1106BA-1104 in combination with BA1106BA 1104 in combination with BA1106BA1106 + BA1104BA1106 in combination with BA1104BA-1106 in combination with BA1104BA 1106 in combination with BA1104
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on BA1104 + BA1106.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BA1104 + BA1106.